CN106729707B - Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof - Google Patents

Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof Download PDF

Info

Publication number
CN106729707B
CN106729707B CN201710044139.XA CN201710044139A CN106729707B CN 106729707 B CN106729707 B CN 106729707B CN 201710044139 A CN201710044139 A CN 201710044139A CN 106729707 B CN106729707 B CN 106729707B
Authority
CN
China
Prior art keywords
yolk antibody
traditional chinese
chinese medicine
chicken
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710044139.XA
Other languages
Chinese (zh)
Other versions
CN106729707A (en
Inventor
范庆增
王建
于小婷
程雪娇
李丽琴
王宇鹏
孙珊珊
王猛
甄盼盼
杨雪
杜宁宁
姬荣曼
焦晓军
余贵菊
崔志刚
张立会
姜淋洁
朱士江
王勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Zhongsheng Challenge Biotechnology Co ltd
Original Assignee
Tianjin Zhongsheng Challenge Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Zhongsheng Challenge Biotechnology Co ltd filed Critical Tianjin Zhongsheng Challenge Biotechnology Co ltd
Priority to CN201710044139.XA priority Critical patent/CN106729707B/en
Publication of CN106729707A publication Critical patent/CN106729707A/en
Application granted granted Critical
Publication of CN106729707B publication Critical patent/CN106729707B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532Agastache, e.g. giant hyssop
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/57Magnoliaceae (Magnolia family)
    • A61K36/575Magnolia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714Aconitum (monkshood)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9064Amomum, e.g. round cardamom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Abstract

The invention provides a composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and a preparation method thereof, wherein the composite yolk antibody is prepared from the following raw materials: 10-50g of traditional Chinese medicine extract, 2000ml of adenovirus yolk antibody and 2g-10g of sodium benzoate. The composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome is added with traditional Chinese medicine extracts comprising monkshood, coptis chinensis, astragalus mongholicus, liquorice, agastache rugosus, eupatorium, rhizoma atractylodis, mangnolia officinalis, amomum cardamomum and the like on the basis of preparing the adenovirus yolk antibody, has high antibody titer, can remarkably repair heart muscle injury of sick chicken, promotes absorption of pericardial effusion, improves the immunity of an organism, prevents secondary infection of the organism and remarkably reduces the death rate of the sick chicken.

Description

Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof
Technical Field
The invention relates to the field of biological products for livestock, in particular to a composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and a preparation method thereof.
Background
The chicken pericardial effusion-hepatitis syndrome is a viral infectious disease which is caused by the group I chicken adenovirus and is characterized by the main pathological changes of the pericardial effusion and the punctate necrosis of the liver, and the current research reports prove that the pathogeny causing the disease is mainly a group I chicken adenovirus serum 4 strain, which causes little economic loss to the poultry breeding in China in the last two years.
The prevention and cure of the above diseases at present mainly depend on vaccines and antibiotics, and conventional adenovirus yolk antibodies. The yolk antibody has a targeted killing effect on viruses, but has no symptomatic treatment effect on symptoms such as myocardial damage and hydropericardium caused by adenovirus infection; antibiotics can inhibit secondary infections in the animal body, but improper use can lead to drug residues and development of drug resistance. Therefore, the compound egg yolk antibody provided by the invention can kill the adenovirus in a targeted manner, can effectively treat pericardial effusion and myocardial injury caused by the adenovirus, has no antibiotic residue, and has important significance for treating both symptoms and root causes of the adenovirus pericardial effusion-hepatitis syndrome.
The application publication No. CN 106075427A is named as a preparation method of avian adenovirus type 1 vaccine and egg yolk antibody, and provides a preparation method of egg yolk antibody for chicken pericardial effusion-hepatitis syndrome, but does not consider the symptomatic treatment effect on symptoms such as myocardial damage and pericardial effusion caused by adenovirus infection, and the application publication No. CN 106065030A is named as an egg yolk antibody for chicken inclusion body hepatitis and a preparation method thereof. Therefore, the compound egg yolk antibody which can kill the adenovirus in a targeted way, can effectively treat the pericardial effusion and myocardial damage caused by the adenovirus, has no antibiotic residue and has important significance for treating both symptoms and root causes of the adenovirus pericardial effusion-hepatitis syndrome is needed.
Disclosure of Invention
In view of the above, the invention aims to provide a technical scheme of a composite egg yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome, and the composite egg yolk antibody prepared by the method is characterized in that the prepared antibody has high titer, can remarkably repair heart muscle injury of sick chicken, promote absorption of pericardial fluid, improve immunity of an organism, prevent secondary infection of the organism and remarkably reduce mortality of the sick chicken.
In order to achieve the purpose, the technical scheme of the invention is realized as follows:
a composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome is prepared from the following raw materials: 10-50g of traditional Chinese medicine extract, 2000ml of adenovirus yolk antibody and 2g-10g of sodium benzoate.
Further, the composite yolk antibody is prepared from the following raw materials: 20-40g of traditional Chinese medicine extract, 1600ml of adenovirus yolk antibody 800-.
Further, the composite yolk antibody is prepared from the following raw materials: 30g of traditional Chinese medicine extract, 1200ml of adenovirus yolk antibody and 6g of sodium benzoate.
Further, the traditional Chinese medicine extract is prepared from the following raw materials in parts by weight: 6-30 parts of monkshood, 6-30 parts of coptis chinensis, 8-40 parts of astragalus membranaceus, 3-15 parts of liquorice, 4-20 parts of agastache rugosus, 4-20 parts of eupatorium fortunei, 4-20 parts of rhizoma atractylodis, 6-30 parts of mangnolia officinalis and 4-20 parts of amomum cardamomum.
Further, the traditional Chinese medicine extract is prepared by the method comprising the following steps:
(1) weighing traditional Chinese medicine raw materials of monkshood, coptis chinensis, astragalus membranaceus, liquorice, agastache rugosus, eupatorium, rhizoma atractylodis, mangnolia officinalis and amomum cardamomum, (cleaning, soaking in cold water for 60min, adding purified water with the weight 15 times of the weight of the raw materials), then adding monkshood into the purified water for decocting, (quickly) heating until the purified water is boiled, continuing to decoct (2 hours) after boiling, then adding coptis chinensis, astragalus membranaceus, liquorice, rhizoma atractylodis, mangnolia officinalis and amomum cardamomum, continuing to decoct (20 minutes), finally adding agastache rugosus and eupatorium, decocting (10 minutes), and stirring once every 5 minutes in the decocting process;
(2) discarding the dregs of the traditional Chinese medicine decoction obtained in the step (1), collecting liquid medicine, cooling at room temperature, centrifuging, discarding the precipitate, and collecting the supernatant;
(3) concentrating the supernatant obtained in the step (2) by 10 times to obtain a traditional Chinese medicine concentrated solution;
(4) and (4) carrying out vacuum freeze drying on the traditional Chinese medicine concentrated solution obtained in the step (3) to obtain a traditional Chinese medicine extract.
Further, the centrifugation conditions in the step (2) are as follows: centrifuge at 4000rpm for 20 minutes.
Further, the adenovirus yolk antibody is prepared by a method comprising the following steps:
(1) selecting hens which are not artificially immunized, have been laid and have normal eggs, and are detected to be negative for newcastle disease virus, avian influenza virus, bursal disease virus and chicken I group adenovirus;
(2) immunizing the hen obtained in the step (1) by using a quadruple inactivated vaccine of newcastle disease virus, avian influenza virus, bursa of fabricius virus and chicken I group adenovirus; wherein, the immunization comprises: primary immunity, secondary immunity and enhanced immunity;
(wherein, the tetrad inactivated vaccine of the chicken Newcastle disease virus, the avian influenza virus, the bursal disease virus and the chicken I group adenovirus is a product of Qingdao Yibang bioengineering Co., Ltd.)
(3) Taking the eggs produced by the immunized hens (7 days later) in the step (2), washing dirt on the surfaces of the eggshells by using tap water, immersing the eggs into a new benzalkonium bromide solution with the volume concentration of 0.5% for disinfection for 30min, taking out the eggs, naturally drying the eggs, wiping the eggshells by using an alcohol cotton ball for surface disinfection, and removing the eggshells) and separating the eggs under the aseptic condition to obtain the egg yolks;
(4) fully stirring the yolk collected in the step (3) to make the yolk be uniform paste;
(5) fully and uniformly mixing the egg yolk liquid obtained in the step (4) with distilled water (in a volume ratio of 1: 4), adjusting the pH to 5.2-5.4 by using 1mol/L HCl, incubating at 4 ℃ (6 hours), centrifuging and taking supernatant;
(6) adding n-caprylic acid into the supernatant obtained in the step (5) to ensure that the volume ratio of the n-caprylic acid in the system is 0.2%, and uniformly mixing;
(7) filtering the solution obtained in the step (6) until the solution is clear, and performing sterilization treatment by using a 0.45 mu m filter membrane.
Further, in the step (2), the first immunization is that each chicken is injected with 1 ml/one tetrad inactivated vaccine in an intramuscular mode; the second immunization is that each chicken is injected with the tetrad inactivated vaccine intramuscularly according to the dose of 1 ml/chicken 14 days after the first immunization; the booster immunization is 7 days after the booster immunization, and each chicken is injected with the tetrad inactivated vaccine intramuscularly according to the dosage of 1 ml/chicken.
Further, the centrifugation conditions in the step (5) are as follows: centrifuge at 4000rpm for 20 minutes.
The invention also provides a preparation method of the composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome, which comprises the following steps:
(1) taking a prescription amount of traditional Chinese medicine extract;
(2) taking a prescription amount of adenovirus yolk antibody;
(3) taking a prescription amount of sodium benzoate;
(4) and (3) adding the traditional Chinese medicine extract in the step (1) and the sodium benzoate in the step (3) into the adenovirus yolk antibody in the step (2), fully stirring the mixture to be uniform, standing, filtering and encapsulating.
Compared with the prior art, the composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and the preparation method thereof have the following advantages:
the prepared composite yolk antibody is added with traditional Chinese medicine extracts including monkshood, coptis chinensis, astragalus, liquorice, agastache rugosus, eupatorium, rhizoma atractylodis, mangnolia officinalis, amomum cardamomum and the like on the basis of preparing the adenovirus yolk antibody. The monkshood can enhance myocardial contraction force, accelerate heart rate, increase cardiac output and myocardial oxygen consumption, and the correct decoction method and the proper amount of liquorice are matched, so that the toxicity of the monkshood can be effectively reduced, and the injury can be reduced; the coptis chinensis has the effect of positive muscle force, and can excite the heart and enhance the myocardial contractility; the two traditional Chinese medicines have remarkable effects on strengthening heart and repairing cardiac injury. The traditional Chinese medicines such as the wrinkled gianthyssop herb, the eupatorium, the rhizoma atractylodis, the officinal magnolia bark, the amomum cardamomum and the like have aromatic smell and warm and dry property, have the functions of diffusing dampness and turbidity, dredging qi, strengthening spleen and waking stomach and the like, are suitable for diseases caused by dampness and turbidity internal resistance, spleen damp stagnation and transportation and transformation disorder, and can obviously promote the absorption of pericardial effusion. The astragalus polysaccharide in the astragalus extract can greatly improve the immunity of organisms, prevent secondary infection and reduce or even eliminate the use of antibiotics. Therefore, the invention has the function of treating both symptoms and root causes of the pericardial effusion-hepatitis syndrome caused by the adenovirus, can quickly reduce the death rate and greatly improve the slaughtering quality of slaughtered chickens.
Detailed Description
Unless defined otherwise, technical terms used in the following examples have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods are conventional methods unless otherwise specified.
The present invention will be described in detail with reference to examples.
Example 1
A composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome is prepared from the following raw materials: 10g of traditional Chinese medicine extract, 400ml of adenovirus yolk antibody and 2g of sodium benzoate.
The traditional Chinese medicine extract is prepared by the method comprising the following steps:
(1) weighing 15 parts of radix aconiti lateralis preparata, 15 parts of coptis chinensis, 20 parts of astragalus membranaceus, 8 parts of liquorice, 10 parts of wrinkled gianthyssop herb, 10 parts of fortune eupatorium herb, 10 parts of rhizoma atractylodis, 15 parts of mangnolia officinalis and 10 parts of amomum cardamomum, cleaning, soaking in cold water for 60min, adding purified water 15 times of the weight of the raw materials, adding the radix aconiti lateralis preparata into the purified water for decocting, quickly heating until the purified water is boiled, continuously decocting for 2 hours after boiling, then adding the coptis chinensis, the astragalus membranaceus, the liquorice, the rhizoma atractylodis, the mangnolia officinalis and the amomum cardamomum, continuously decocting for 20 minutes, finally adding the wrinkled gianthyssop herb and the fortune eupatorium herb for decocting for 10 minutes, and stirring once every 5 minutes in the decocting process;
(2) discarding the dregs of the traditional Chinese medicine decoction obtained in the step (1), collecting liquid medicine, cooling at room temperature, centrifuging at 4000rpm for 20 minutes, discarding the precipitate, and collecting the supernatant;
(3) concentrating the supernatant obtained in the step (2) by 10 times to obtain a traditional Chinese medicine concentrated solution;
(4) and (4) carrying out vacuum freeze drying on the traditional Chinese medicine concentrated solution obtained in the step (3) to obtain a traditional Chinese medicine extract.
The adenovirus yolk antibody is prepared by the method comprising the following steps:
(1) selecting hens which are not artificially immunized, have been laid and have normal eggs, and are detected to be negative for newcastle disease virus, avian influenza virus, bursal disease virus and chicken I group adenovirus;
(2) immunizing the hen obtained in the step (1) by using a quadruple inactivated vaccine of newcastle disease virus, avian influenza virus, bursal disease virus and chicken I group adenovirus produced by Qingdao Yibang bioengineering limited company; wherein, the immunization comprises: primary immunity, secondary immunity and enhanced immunity;
the first immunization is as follows: each chicken is injected with 1 ml/one tetrad inactivated vaccine intramuscularly;
the secondary immunity is as follows: after 14 days of the first immunization, each chicken is injected with the tetrad inactivated vaccine intramuscularly according to the dose of 1 ml/chicken;
the enhanced immunity is as follows: 7 days after the booster immunization, each chicken is injected with the tetrad inactivated vaccine intramuscularly according to the dose of 1 ml/chicken;
(3) taking the eggs produced 7 days after the hens are immunized in the step (2), washing off dirt on the surfaces of the eggshells by using tap water, immersing the eggs into a new benzalkonium bromide solution with the volume concentration of 0.5% for disinfection for 30min, taking out the eggs, naturally drying the eggs, wiping the eggshells by using an alcohol cotton ball for surface disinfection, removing the eggshells, and separating the eggshells under aseptic conditions to obtain the egg yolks;
(4) fully stirring the yolk collected in the step (3) to make the yolk be uniform paste;
(5) fully and uniformly mixing the egg yolk liquid obtained in the step (4) with distilled water according to the volume ratio of 1:4, adjusting the pH to 5.2-5.4 by using 1mol/L HCl, incubating for 6 hours at the temperature of 4 ℃, centrifuging for 20 minutes at 4000rpm, and taking the supernatant after centrifugation;
(6) adding n-caprylic acid into the supernatant obtained in the step (5) to ensure that the volume ratio of the n-caprylic acid in the system is 0.2%, and uniformly mixing;
(7) filtering the solution obtained in the step (6) until the solution is clear, and performing sterilization treatment by using a 0.45 mu m filter membrane.
A preparation method of a composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome comprises the following steps:
(1) taking a prescription amount of traditional Chinese medicine extract;
(2) taking a prescription amount of adenovirus yolk antibody;
(3) taking a prescription amount of sodium benzoate;
(4) and (3) adding the traditional Chinese medicine extract in the step (1) and the sodium benzoate in the step (3) into the adenovirus yolk antibody in the step (2), fully stirring the mixture to be uniform, standing, filtering and encapsulating.
Example 2
A composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome is prepared from the following raw materials: 20g of traditional Chinese medicine extract, 800ml of adenovirus yolk antibody and 4g of sodium benzoate.
The preparation method of the traditional Chinese medicine extract, the preparation method of the adenovirus yolk antibody and the preparation method of the composite yolk antibody are the same as those in embodiment 1, and are not described again.
Example 3
A composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome is prepared from the following raw materials: 30g of traditional Chinese medicine extract, 1200ml of adenovirus yolk antibody and 6g of sodium benzoate.
The preparation method of the traditional Chinese medicine extract, the preparation method of the adenovirus yolk antibody and the preparation method of the composite yolk antibody are the same as those in embodiment 1, and are not described again.
The complex yolk antibodies obtained in example 1, example 2 and example 3 were subjected to the following tests:
250 white feather broilers of 25-day age are taken, disease materials are actually the chicken pericardial effusion-hepatitis syndrome caused by the adenovirus group I and serum type 4 through laboratory detection, and the 250 white feather broilers are randomly divided into a blank group, a control group, a test group 1, a test group 2 and a test group 3, wherein each group comprises 50 white feather broilers. The blank group did not use any drug, the control group was orally administered with adenovirus yolk antibody, the test group 1 was orally administered with the complex yolk antibody prepared in example 1, the test group 2 was orally administered with the complex yolk antibody prepared in example 2, and the test group 3 was orally administered with the complex yolk antibody prepared in example 3, all at a dose of 1.5 ml/mouse, and the death and the slaughter weight of each group were observed and recorded, respectively, and the results are shown in table 1.
TABLE 1 death and slaughter weight of white-feather chickens
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included in the scope of the present invention.

Claims (7)

1. A composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome is characterized in that: the composite yolk antibody is prepared from the following raw materials: 10-50g of traditional Chinese medicine extract, 2000ml of adenovirus yolk antibody and 2g-10g of sodium benzoate, wherein the traditional Chinese medicine extract is prepared from the following raw materials in parts by weight: 6-30 parts of monkshood, 6-30 parts of coptis chinensis, 8-40 parts of astragalus membranaceus, 3-15 parts of liquorice, 4-20 parts of agastache rugosus, 4-20 parts of eupatorium fortunei, 4-20 parts of rhizoma atractylodis, 6-30 parts of mangnolia officinalis and 4-20 parts of amomum cardamomum;
the traditional Chinese medicine extract is prepared by the following steps:
(1) weighing traditional Chinese medicine raw materials of monkshood, coptis chinensis, astragalus mongholicus, liquorice, agastache rugosus, eupatorium fortunei, rhizoma atractylodis, mangnolia officinalis and amomum cardamomum, then adding monkshood into purified water for decoction, heating until the purified water is boiled, continuing to decoct after boiling, then adding coptis chinensis, astragalus mongholicus, liquorice, rhizoma atractylodis, mangnolia officinalis and amomum cardamomum, continuing to decoct, finally adding agastache rugosus and eupatorium fortunei for decoction, and stirring once every 5 minutes in the decoction process;
(2) discarding the dregs of the traditional Chinese medicine decoction obtained in the step (1), collecting liquid medicine, cooling at room temperature, centrifuging, discarding the precipitate, and collecting the supernatant;
(3) concentrating the supernatant obtained in the step (2) by 10 times to obtain a traditional Chinese medicine concentrated solution;
(4) carrying out vacuum freeze drying on the traditional Chinese medicine concentrated solution obtained in the step (3) to obtain a traditional Chinese medicine extract;
the preparation method of the composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome comprises the following steps:
(1) taking a prescription amount of traditional Chinese medicine extract;
(2) taking a prescription amount of adenovirus yolk antibody;
(3) taking a prescription amount of sodium benzoate;
(4) and (3) adding the traditional Chinese medicine extract in the step (1) and the sodium benzoate in the step (3) into the adenovirus yolk antibody in the step (2), fully stirring the mixture to be uniform, standing, filtering and encapsulating.
2. The composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome according to claim 1, is characterized in that: the composite yolk antibody is prepared from the following raw materials: 20-40g of traditional Chinese medicine extract, 1600ml of adenovirus yolk antibody 800-.
3. The composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome according to claim 1, is characterized in that: the composite yolk antibody is prepared from the following raw materials: 30g of traditional Chinese medicine extract, 1200ml of adenovirus yolk antibody and 6g of sodium benzoate.
4. The composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome according to claim 1, is characterized in that: the centrifugation conditions in the step (2) are as follows: centrifuge at 4000rpm for 20 minutes.
5. The composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome according to any one of claims 1-3, wherein: the adenovirus yolk antibody is prepared by the method comprising the following steps:
(1) selecting hens which are not artificially immunized, have been laid and have normal eggs, and are detected to be negative for newcastle disease virus, avian influenza virus, bursal disease virus and chicken I group adenovirus;
(2) immunizing the hen obtained in the step (1) by using a quadruple inactivated vaccine of newcastle disease virus, avian influenza virus, bursa of fabricius virus and chicken I group adenovirus; wherein, the immunization comprises: primary immunity, secondary immunity and enhanced immunity;
(3) taking the eggs produced by the immunized hens in the step (2), and separating under an aseptic condition to obtain egg yolks;
(4) fully stirring the yolk collected in the step (3) to make the yolk be uniform paste;
(5) fully and uniformly mixing the egg yolk liquid obtained in the step (4) with distilled water, adjusting the pH to 5.2-5.4 by using 1mol/L HCl, incubating at 4 ℃, centrifuging and taking supernatant;
(6) adding n-caprylic acid into the supernatant obtained in the step (5) to ensure that the volume ratio of the n-caprylic acid in the system is 0.2%, and uniformly mixing;
(7) filtering the solution obtained in the step (6) until the solution is clear, and performing sterilization treatment by using a 0.45 mu m filter membrane.
6. The composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome according to the claim 5, is characterized in that: in the step (2), the first immunization is that each chicken is injected with 1 ml/one tetrad inactivated vaccine intramuscularly; the second immunization is that each chicken is injected with the tetrad inactivated vaccine intramuscularly according to the dose of 1 ml/chicken 14 days after the first immunization; the booster immunization is 7 days after the booster immunization, and each chicken is injected with the tetrad inactivated vaccine intramuscularly according to the dosage of 1 ml/chicken.
7. The composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome according to the claim 5, is characterized in that: the centrifugation conditions in the step (5) are as follows: centrifuge at 4000rpm for 20 minutes.
CN201710044139.XA 2017-01-19 2017-01-19 Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof Active CN106729707B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710044139.XA CN106729707B (en) 2017-01-19 2017-01-19 Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710044139.XA CN106729707B (en) 2017-01-19 2017-01-19 Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof

Publications (2)

Publication Number Publication Date
CN106729707A CN106729707A (en) 2017-05-31
CN106729707B true CN106729707B (en) 2021-08-24

Family

ID=58945117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710044139.XA Active CN106729707B (en) 2017-01-19 2017-01-19 Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106729707B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105535198A (en) * 2016-01-29 2016-05-04 青岛信诺邦生物科技有限公司 Traditional Chinese medicine composition for treating poultry hydropericardium
CN105770892A (en) * 2016-02-04 2016-07-20 烟台金海药业有限公司 Preparation method of biological veterinary drug for preventing and treating hydropericardium hepatitis syndrome in chickens
CN105797156A (en) * 2016-03-15 2016-07-27 烟台金海药业有限公司 Preparation method of antigen-antibody complex preparation for preventing and treating HHS
CN106075427A (en) * 2016-06-30 2016-11-09 武汉中博生物股份有限公司 1 type aviadenovirus vaccine, the preparation method of yolk antibody
CN106215100A (en) * 2016-08-22 2016-12-14 中国农业科学院兰州畜牧与兽药研究所 A kind of Chinese medicine composition preventing and treating poultry pericardial effusion hepatitis syndrome and its preparation method and application

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105535198A (en) * 2016-01-29 2016-05-04 青岛信诺邦生物科技有限公司 Traditional Chinese medicine composition for treating poultry hydropericardium
CN105770892A (en) * 2016-02-04 2016-07-20 烟台金海药业有限公司 Preparation method of biological veterinary drug for preventing and treating hydropericardium hepatitis syndrome in chickens
CN105797156A (en) * 2016-03-15 2016-07-27 烟台金海药业有限公司 Preparation method of antigen-antibody complex preparation for preventing and treating HHS
CN106075427A (en) * 2016-06-30 2016-11-09 武汉中博生物股份有限公司 1 type aviadenovirus vaccine, the preparation method of yolk antibody
CN106215100A (en) * 2016-08-22 2016-12-14 中国农业科学院兰州畜牧与兽药研究所 A kind of Chinese medicine composition preventing and treating poultry pericardial effusion hepatitis syndrome and its preparation method and application

Also Published As

Publication number Publication date
CN106729707A (en) 2017-05-31

Similar Documents

Publication Publication Date Title
CN102827275B (en) Method for preparing duck virus hepatitis divalent refined egg yolk antibody
CN103585626B (en) Preparation method for newcastle disease and infectious bursal disease bigeminal composite inactivated vaccine
CN104208673B (en) A kind of fowl antiviral composition, lyophilized powder, preparation method and application
CN103495167B (en) A kind of preparation method of chicken infection bursal disease composite live vaccine
CN101780153B (en) Traditional Chinese drug composition for pig and preparation method and application thereof
CN103833848A (en) Egg yolk antibody for preventing and curing muscovy duck parvovirus diseases
CN102743751A (en) Preparation method of newcastle diseases, infectious bursal disease bigeminy high immunity-yolk-antibody lyophilized powder
CN111420042A (en) Duck circovirus and adenovirus bivalent inactivated vaccine and preparation method of yolk antibody thereof
CN103860616A (en) Manyprickle Acathopanax Root extrat, and preparation method and application thereof
CN101259273A (en) Yolk antibody feed additive and injection for resisting canine distemper and canine parvovirus disease and preparation thereof
CN102988490A (en) Application of Shuanghuanglian oral liquor in preparation of medicine for treating and preventing poultry virosis
CN100586454C (en) Chinese medicine composition for birds, preparing method and application of the same
CN102716327B (en) Immunopotentiator for poultry rearing
CN1330330C (en) Antivirus medicinal composition, preparation method and use
CN106729707B (en) Composite yolk antibody for preventing and treating chicken pericardial effusion-hepatitis syndrome and preparation method thereof
CN103720932B (en) One boar Chinese medicine composition and its preparation method and application
CN104888213A (en) Preparation method of classical swine fever spleen-lymph-sourced compound living vaccine
CN106924352B (en) Application of traditional Chinese medicine composition
CN105770892A (en) Preparation method of biological veterinary drug for preventing and treating hydropericardium hepatitis syndrome in chickens
CN103599534A (en) Preparation method and use of poultry vaccine-specific pig spleen transfer factor
CN101690821B (en) Immune protective agent of attenuated living vaccine against infectious bursal disease and preparation method thereof
CN103143010A (en) Triad inactivated vaccine for newcastle disease and bird flu (H9 subtype) and escherichia coli disease and preparation method thereof
CN110448586A (en) A kind of Astragalus Root P.E and its preparation method and application
CN103784685B (en) Chinese medicine composition for the treatment of livestock and poultry virus sexually transmitted disease and its preparation method and application
CN104208683A (en) Pharmaceutical composition for preventing duck viral diseases, freeze-dried powder, preparation method and applications of the composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant